Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Berli Jucker Public Company Limited (BJC-R.BK)
Bangkok, TH
Berli Jucker Public Company Limited, a diversified Thai conglomerate founded in 1882 and headquartered in Bangkok, operates as a subsidiary of TCC Corporation Company Limited. Its extensive operations encompass manufacturing, distribution, and service provision across critical sectors such as packaging, consumer goods, healthcare, technical solutions, modern retail supply chains, and various other group enterprises within Thailand. In its packaging division, BJC manages the entire lifecycle from design and manufacturing to marketing and distribution of various containers, including glass and plastic products, as well as aluminum cans. The consumer business involves the distribution of a broad portfolio of personal care products, featuring brands like Cellox, Zilk, and Maxmo (for facial tissues and toilet papers), Parrot soaps, and Dermapon baby soaps. The company also distributes popular snack items such as Tasto potato chips, Dozo rice crackers, and Party and Campus extruded snacks. Complementing its product distribution, BJC provides extensive logistics services, including warehousing, transportation, customs brokerage, and freight forwarding. The product offerings extend to a wide array of food items like snacks, beverages, packaged fruits, dairy, and yogurt, alongside non-food essentials such as personal care and household products, stationery, and office equipment. Within the healthcare and technical sector, BJC serves as a crucial importer and distributor of a comprehensive range of medical and health products. This includes pharmaceuticals, medical supplies, cosmeceuticals, food supplements, and general health products designed to treat conditions affecting the kidney, hematology, cardiovascular, endocrine, genitourinary, skeletal, infectious diseases, oncology, pediatric health, and beauty. Furthermore, they supply advanced medical devices, such as computed radiography, ultrasound, digital mammography, X-ray, and 3D medical image processing systems, in addition to laboratory information systems. BJC's other ventures include supplying ingredients for the bakery, food, nutraceutical, and cosmetic industries; distributing industrial chemicals and refrigerants; engaging in e-commerce; and offering consultancy, design, installation, and after-sales support for crane and solar rooftop systems, as well as weighing control systems.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.40% | -1.40% | -6.00% | -14.55% | -18.02% | -28.79% | -39.74% | -62.89% | -58.22% | -56.40% | +243.90% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Conglomerates: +6.1%-2.4% Q1'26: -0.8% (vs Q1'25)
-
EPS growth Conglomerates: +16.9%+0.0% Q1'26: -3.7% (vs Q1'25)
-
FCF margin FCF growth · Conglomerates: +35.9%-5.4% Q1'26: +5.4% (vs Q1'25)
-
EBIT margin Conglomerates: +9.0%-0.5% Q1'26: -2.1% (vs Q1'25)
-
ROIC Conglomerates: +4.7%-0.2% Q1'26: -0.9% (vs Q1'25)
-
Share dilution Conglomerates: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Conglomerates: 1.28×20.86× Q1'26: 26.57× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 8 Rev. Ana. 1 EPS Ana. |
Dec 2027 9 Rev. Ana. 1 EPS Ana. |
Dec 2028 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
42.89B
est: 43.88B (-2.2%)
|
125.33B
est: 130.54B (-4.0%)
|
149.16B
est: 153.15B (-2.6%)
|
156.14B
est: 159.50B (-2.1%)
|
158.01B
est: 160.28B (-1.4%)
|
144.73B
est: 148.24B (-2.4%)
|
138.46B
est: 141.47B (-2.1%)
|
150.34B
est: 152.70B (-1.5%)
|
154.67B
est: 155.60B (-0.6%)
|
157.73B
est: 159.83B (-1.3%)
|
154.02B
est: 155.67B (-1.1%)
|
159.00B
152.09B – 166.60B
+2.1% YoY
|
165.62B
153.85B – 182.50B
+4.2% YoY
|
177.89B
167.67B – 191.28B
+7.4% YoY
|
| EBITDA |
6.01B
est: 5.89B (+1.9%)
|
14.85B
est: 17.54B (-15.3%)
|
17.72B
est: 20.58B (-13.9%)
|
18.85B
est: 21.43B (-12.0%)
|
18.86B
est: 21.53B (-12.4%)
|
18.27B
est: 19.92B (-8.3%)
|
19.12B
est: 19.01B (+0.6%)
|
20.01B
est: 20.51B (-2.4%)
|
20.54B
est: 20.90B (-1.8%)
|
22.32B
est: 19.20B (+16.3%)
|
8.48B
est: 18.70B (-54.6%)
|
19.10B
18.27B – 20.01B
+2.1% YoY
|
19.89B
18.48B – 21.92B
+4.2% YoY
|
21.37B
20.14B – 22.98B
+7.4% YoY
|
| EBIT |
4.35B
est: 3.31B (+31.4%)
|
10.54B
est: 9.84B (+7.1%)
|
12.74B
est: 11.54B (+10.4%)
|
13.76B
est: 12.02B (+14.5%)
|
13.57B
est: 12.08B (+12.3%)
|
10.77B
est: 11.17B (-3.6%)
|
10.05B
est: 10.66B (-5.7%)
|
11.00B
est: 11.51B (-4.4%)
|
11.55B
est: 11.73B (-1.5%)
|
12.93B
est: 9.52B (+35.9%)
|
-725.66M
est: 9.27B (-107.8%)
|
9.47B
9.06B – 9.92B
+2.1% YoY
|
9.86B
9.16B – 10.87B
+4.2% YoY
|
10.59B
9.98B – 11.39B
+7.4% YoY
|
| Net Income |
2.79B
est: 5.97B (-53.3%)
|
4.00B
est: 4.58B (-12.7%)
|
5.21B
est: 5.19B (+0.4%)
|
6.65B
est: 6.46B (+3.0%)
|
7.28B
est: 6.82B (+6.7%)
|
4.00B
est: 4.26B (-6.0%)
|
3.58B
est: 3.66B (-2.1%)
|
5.01B
est: 4.94B (+1.4%)
|
4.79B
est: 4.86B (-1.3%)
|
4.00B
est: 4.31B (-7.2%)
|
4.01B
est: 4.33B (-7.5%)
|
4.78B
4.42B – 5.24B
+10.2% YoY
|
5.22B
4.83B – 5.73B
+9.4% YoY
|
6.10B
5.64B – 6.70B
+16.8% YoY
|
| SGA |
7.18B
est: 8.88B (-19.1%)
|
23.53B
est: 26.42B (-10.9%)
|
30.69B
est: 30.99B (-1.0%)
|
32.26B
est: 32.28B (0.0%)
|
33.22B
est: 32.43B (+2.4%)
|
29.69B
est: 30.00B (-1.0%)
|
27.62B
est: 28.63B (-3.5%)
|
29.89B
est: 30.90B (-3.3%)
|
31.65B
est: 31.49B (+0.5%)
|
32.15B
est: 32.46B (-1.0%)
|
32.17B
est: 31.62B (+1.8%)
|
32.30B
30.89B – 33.84B
+2.1% YoY
|
33.64B
31.25B – 37.07B
+4.2% YoY
|
36.13B
34.06B – 38.85B
+7.4% YoY
|
| EPS |
1.62
est: 1.49 (+8.7%)
|
1.28
est: 1.14 (+12.0%)
|
1.31
est: 1.29 (+1.2%)
|
1.66
est: 1.61 (+3.0%)
|
1.82
est: 1.70 (+6.9%)
|
1.00
est: 1.06 (-5.9%)
|
0.89
est: 0.91 (-2.6%)
|
1.25
est: 1.23 (+1.4%)
|
1.20
est: 1.21 (-1.0%)
|
1.00
est: 1.08 (-7.0%)
|
1.00
est: 1.08 (-7.5%)
|
1.19
1.10 – 1.31
+10.2% YoY
|
1.30
1.21 – 1.43
+9.4% YoY
|
1.52
1.41 – 1.67
+16.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C+ | 2/5 | 5/5 | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C+ | 2/5 | 5/5 | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C+ | 2/5 | 5/5 | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 5/5 | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C+ | 2/5 | 5/5 | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 5/5 | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | B- | 2/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | B- | 2/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | B- | 2/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | B- | 2/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | B- | 2/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | B- | 2/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | B- | 2/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | B- | 2/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | B- | 2/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | B- | 2/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI Thailand ETF THD | 0.26% | 933.5K | 0.59% |
| 2 | WisdomTree Emerging Markets SmallCap Dividend Fund DGS | 0.08% | 1.46M | 0.58% |
| 3 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.04% | 29.9K | 0.74% |
| 4 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.03% | 87.1K | 0.74% |
| 5 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.02% | 125.5K | 0.55% |
| 6 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.01% | 19.9K | 0.56% |
| 7 | Franklin FTSE Asia ex China ex Japan UCITS ETF FLQA.L | 0.01% | 28.1K | 0.14% |
| 8 | Goldman Sachs MarketBeta Total International Equity ETF GXUS | 0.01% | 31.7K | 0.18% |
| 9 | iShares MSCI EM IMI Screened UCITS ETF SEDM.L | 0.00% | 46.5K | 0.18% |
| 10 | iShares Core MSCI Emerging Markets IMI Index ETF XEC.TO | 0.00% | 104.1K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Prasert Maekwatana | Non-Executive Director | 900.0K | male |
| Apinya Narasawat | Member of Management Board | — | female |
| Aswin Techajareonvikul | Executive Vice Chairman of Management Board & Executive Director | — | male |
| Boonsak Stitmannaithum | SEVP of Logistics & Engineering Business and Acting SVP of Graphic System Div. | — | male |
| Hemmawan Poonphol | Group Chief of Staff, Head of Procurement & Member of Management Board | — | female |
| Kamonwan Sivaraksa | Chief Legal and Compliance Officer & Member of Management Board | — | female |
| Pattaphong Iamsuro | Member of Management Board | — | male |
| Prapakon Thongtheppairot | Executive Director | — | male |
| Teera Werathamsathit | Group Chief People Officer & Member of Management Board | — | male |
| Thapanee Techajareonvikul | Chief Executive Officer, President, Chairman of Management Board & Director | — | female |
| Thirasakdi Nathikanchanalab | Director | — | male |
| Tul Wongsuphasawat | Group Chief Brand & Commercial Officer, Acting Chief Mkting Officer and Member of Management Board | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BJC-R.BK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
